Hassan Masoudpour, J. Wassef, Alain Cagaanan, J. Tzeng, Jenna Gillen, Rachelle Leong
{"title":"Necrotizing Breast Infection: A Rare Entity and a Management Challenge","authors":"Hassan Masoudpour, J. Wassef, Alain Cagaanan, J. Tzeng, Jenna Gillen, Rachelle Leong","doi":"10.14740/jcs474","DOIUrl":"https://doi.org/10.14740/jcs474","url":null,"abstract":"","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":" 30","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141130591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Applying Bloom’s Taxonomy in Orthopedic Clinical Education: Examples for Daily Practice","authors":"Wisam Suhail Al Obaidi, F. Tuma","doi":"10.14740/jcs477","DOIUrl":"https://doi.org/10.14740/jcs477","url":null,"abstract":"","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":" 12","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141131939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Colorectal Surgery Outcomes in Patients With Connective Tissue Disease: Insights From a National Database Analysis","authors":"Adejoke Johnson, Ezekiel J Akpan, Marianne Solano, Medha Rajamanuri, Chukwunonso Ezeani, Khan Zinobia, Moses Bachan","doi":"10.14740/jcs476","DOIUrl":"https://doi.org/10.14740/jcs476","url":null,"abstract":"","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"3 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141141801","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jacqueline Renee Booth, Sahar Emami Naeini, Hesam Khodadadi, Evila Lopes Salles, Thalyta Xavier de Medeiros, Austin DeLaney, Edward Jim Kruse, Achuta Kumar Guddati, Babak Baban, James Kenneth Byrd
Background: Gastrostomy tube placement is sometimes necessary during chemoradiation for head and neck cancer (HNC), but it is associated with worse swallowing outcomes. Despite best efforts, the need for gastrostomy cannot be perfectly predicted, and some patients develop the need for gastrostomy while undergoing chemotherapy. To date, the impact of cisplatin on gastrostomy site healing has not been investigated. The aim of this study is to compare the levels of procollagen, connective tissue growth factor (CTGF), and CD26 in the gastrostomy sites of mice at varying timepoints after cisplatin versus saline. Methods: For this study we used 32 C57BL/6 mice. Cisplatin (1 mg/kg) was injected intraperitoneally into the mice from treatment groups. Control groups received the same volume of normal saline intraperitoneally. Mice underwent gastrostomy tube placement at 7, 10, 14, and 17 days post cisplatin or saline therapy. Ten days after gastrostomy placement, mice were sacrificed, and the gastrostomy site tissue was examined. We measured the levels of procollagen type 1, CTGF, and CD26 by flow cytometry. Massons trichrome stain was used for qualitative comparison of collagen formation in surgical site tissue. Results: Massons trichrome staining showed more collagen formation in surgical site tissue at 17 versus 7 days post-cisplatin. Levels of procollagen type 1 by flow cytometry were significantly higher in the control group compared to the treatment group (P < 0.0001) for each time point. There was a statistically significant difference in procollagen type 1 between the 7 days post-chemotherapy group and the 17 days post-chemotherapy group (P = 0.0024). The percentage of cells with procollagen, CTGF, and CD26 in the 7 days post-saline control group were similar to the percentage in the 14 days post-cisplatin treatment group. Conclusions: CTGF, CD26, and procollagen were decreased by cisplatin in gastrostomy site tissue at each time point, but levels 14 days after a cisplatin treatment approximate the levels 7 days after saline. These results suggest that it is safe to proceed with gastrostomy tube placement 14 - 17 days after cisplatin because the CTGF, CD26, and procollagen levels approximate the levels 7 days after saline. Additional studies are needed to extrapolate to humans. J Curr Surg. 2023;13(1):6-11 doi: https://doi.org/10.14740/jcs468
{"title":"The Effects of Cisplatin on Gastrostomy Site Healing","authors":"Jacqueline Renee Booth, Sahar Emami Naeini, Hesam Khodadadi, Evila Lopes Salles, Thalyta Xavier de Medeiros, Austin DeLaney, Edward Jim Kruse, Achuta Kumar Guddati, Babak Baban, James Kenneth Byrd","doi":"10.14740/jcs468","DOIUrl":"https://doi.org/10.14740/jcs468","url":null,"abstract":"Background: Gastrostomy tube placement is sometimes necessary during chemoradiation for head and neck cancer (HNC), but it is associated with worse swallowing outcomes. Despite best efforts, the need for gastrostomy cannot be perfectly predicted, and some patients develop the need for gastrostomy while undergoing chemotherapy. To date, the impact of cisplatin on gastrostomy site healing has not been investigated. The aim of this study is to compare the levels of procollagen, connective tissue growth factor (CTGF), and CD26 in the gastrostomy sites of mice at varying timepoints after cisplatin versus saline. Methods: For this study we used 32 C57BL/6 mice. Cisplatin (1 mg/kg) was injected intraperitoneally into the mice from treatment groups. Control groups received the same volume of normal saline intraperitoneally. Mice underwent gastrostomy tube placement at 7, 10, 14, and 17 days post cisplatin or saline therapy. Ten days after gastrostomy placement, mice were sacrificed, and the gastrostomy site tissue was examined. We measured the levels of procollagen type 1, CTGF, and CD26 by flow cytometry. Massons trichrome stain was used for qualitative comparison of collagen formation in surgical site tissue. Results: Massons trichrome staining showed more collagen formation in surgical site tissue at 17 versus 7 days post-cisplatin. Levels of procollagen type 1 by flow cytometry were significantly higher in the control group compared to the treatment group (P < 0.0001) for each time point. There was a statistically significant difference in procollagen type 1 between the 7 days post-chemotherapy group and the 17 days post-chemotherapy group (P = 0.0024). The percentage of cells with procollagen, CTGF, and CD26 in the 7 days post-saline control group were similar to the percentage in the 14 days post-cisplatin treatment group. Conclusions: CTGF, CD26, and procollagen were decreased by cisplatin in gastrostomy site tissue at each time point, but levels 14 days after a cisplatin treatment approximate the levels 7 days after saline. These results suggest that it is safe to proceed with gastrostomy tube placement 14 - 17 days after cisplatin because the CTGF, CD26, and procollagen levels approximate the levels 7 days after saline. Additional studies are needed to extrapolate to humans. J Curr Surg. 2023;13(1):6-11 doi: https://doi.org/10.14740/jcs468","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"32 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135639386","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Mitchell Hughes, Shelby Cornelius, Allen Kadado, Reid Chambers, Brian Hall, Joseph D. Tobias
Background: Remimazolam is a benzodiazepine that has recently been released for clinical use. Similar to midazolam, it has sedative, anxiolytic, and amnestic properties. However, its metabolism is different as it undergoes metabolism by tissue esterases with a half-life of 5 - 10 min and a limited context-sensitive half-life. Methods: We retrospectively reviewed our experience with the use of remimazolam as an adjunctive to general anesthesia during spine surgery. Results: The study cohort included 40 patients, ranging in age from 11 to 35 years and in weight from 21 to 126 kg. Remimazolam was added as an adjunct to maintenance anesthesia with propofol, desflurane, or dexmedetomidine/ketamine at a starting dose of 2.5 - 10 µg/kg/min (median dose 5 µg/kg/min). Maintenance doses ranged from 1.5 to 30 µg/kg/min (median dose 8 µg/kg/min). Remimazolam was infused for an average of 5.1 h per patient or a total of 203 h of infusion in the 40 patients. With the infusion of remimazolam, the requirements for the volatile agent or propofol were decreased by approximately 40-50%. No adverse effects related to remimazolam were noted. Conclusions: Remimazolam is an effective adjunct to general anesthesia during spinal surgery, resulting in a significant decrease in requirements for propofol or volatile anesthetic agents. J Curr Surg. 2023;13(1):1-5 doi: https://doi.org/10.14740/jcs472
{"title":"Remimazolam as an Adjunct to General Anesthesia During Spine Surgery in Adolescents","authors":"Mitchell Hughes, Shelby Cornelius, Allen Kadado, Reid Chambers, Brian Hall, Joseph D. Tobias","doi":"10.14740/jcs472","DOIUrl":"https://doi.org/10.14740/jcs472","url":null,"abstract":"Background: Remimazolam is a benzodiazepine that has recently been released for clinical use. Similar to midazolam, it has sedative, anxiolytic, and amnestic properties. However, its metabolism is different as it undergoes metabolism by tissue esterases with a half-life of 5 - 10 min and a limited context-sensitive half-life. Methods: We retrospectively reviewed our experience with the use of remimazolam as an adjunctive to general anesthesia during spine surgery. Results: The study cohort included 40 patients, ranging in age from 11 to 35 years and in weight from 21 to 126 kg. Remimazolam was added as an adjunct to maintenance anesthesia with propofol, desflurane, or dexmedetomidine/ketamine at a starting dose of 2.5 - 10 µg/kg/min (median dose 5 µg/kg/min). Maintenance doses ranged from 1.5 to 30 µg/kg/min (median dose 8 µg/kg/min). Remimazolam was infused for an average of 5.1 h per patient or a total of 203 h of infusion in the 40 patients. With the infusion of remimazolam, the requirements for the volatile agent or propofol were decreased by approximately 40-50%. No adverse effects related to remimazolam were noted. Conclusions: Remimazolam is an effective adjunct to general anesthesia during spinal surgery, resulting in a significant decrease in requirements for propofol or volatile anesthetic agents. J Curr Surg. 2023;13(1):1-5 doi: https://doi.org/10.14740/jcs472","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"11 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135639253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Christopher Kim, Daniel Bushyhead, Edward Chan, Howard Huang, Ray Chihara, Ahmad Goodarzi, Simon Yau, Jihad Youssef, Thomas Macgillivray, Erik Suarez, Philip Chou, Gulchin Ergun
Background: Patients with coronavirus disease 2019 (COVID-19)-associated respiratory failure undergoing lung transplantation is an emerging subset of transplant patients in which gastroesophageal reflux disease (GERD) pre- or post-transplant is not well characterized. Methods: We retrospectively evaluated patients undergoing lung transplant for COVID-19, with attention to pre- and post-operative physiological testing for GERD. Results: Seventeen patients were identified who had undergone lung transplant for COVID-19. No patient underwent pre-transplant GERD testing. Post-transplant, 70.5% (12/17) patients reported reflux symptoms confirmed with additional testing. Three patients underwent anti-reflux surgery (ARS) based on results of testing, and none had complications or symptom-based recurrence of reflux. Conclusion: Our study depicts a unique cohort of patients who were unable to undergo pre-transplant testing for GERD in the setting of a global pandemic, and who were routinely assessed and managed post-transplant. J Curr Surg. 2023;13(1):12-16 doi: https://doi.org/10.14740/jcs467
{"title":"Impact of Gastroesophageal Reflux Disease on Patients Undergoing Lung Transplantation for COVID-19: A Single Institution Retrospective Study","authors":"Christopher Kim, Daniel Bushyhead, Edward Chan, Howard Huang, Ray Chihara, Ahmad Goodarzi, Simon Yau, Jihad Youssef, Thomas Macgillivray, Erik Suarez, Philip Chou, Gulchin Ergun","doi":"10.14740/jcs467","DOIUrl":"https://doi.org/10.14740/jcs467","url":null,"abstract":"Background: Patients with coronavirus disease 2019 (COVID-19)-associated respiratory failure undergoing lung transplantation is an emerging subset of transplant patients in which gastroesophageal reflux disease (GERD) pre- or post-transplant is not well characterized. Methods: We retrospectively evaluated patients undergoing lung transplant for COVID-19, with attention to pre- and post-operative physiological testing for GERD. Results: Seventeen patients were identified who had undergone lung transplant for COVID-19. No patient underwent pre-transplant GERD testing. Post-transplant, 70.5% (12/17) patients reported reflux symptoms confirmed with additional testing. Three patients underwent anti-reflux surgery (ARS) based on results of testing, and none had complications or symptom-based recurrence of reflux. Conclusion: Our study depicts a unique cohort of patients who were unable to undergo pre-transplant testing for GERD in the setting of a global pandemic, and who were routinely assessed and managed post-transplant. J Curr Surg. 2023;13(1):12-16 doi: https://doi.org/10.14740/jcs467","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"20 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135639383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Shashi Praba Abeyrathna, C. Kulathilake, I. Wijesiriwardena
{"title":"Prevalence and Associated Factors of Post-Thrombotic Syndrome in Patients With Deep Vein Thrombosis","authors":"Shashi Praba Abeyrathna, C. Kulathilake, I. Wijesiriwardena","doi":"10.14740/jcs459","DOIUrl":"https://doi.org/10.14740/jcs459","url":null,"abstract":"","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"56 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79474095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Zinger, A. Davidson, N. Sylvetsky, Y. Levy, A. Peyser
{"title":"Cost Analysis of a Fracture Liaison Service: A Prospective Study for Secondary Prevention After Fractures of the Hip","authors":"G. Zinger, A. Davidson, N. Sylvetsky, Y. Levy, A. Peyser","doi":"10.14740/jcs460","DOIUrl":"https://doi.org/10.14740/jcs460","url":null,"abstract":"","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"46 7 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77485039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nicholson Brant, M. Darwish, H. Osman, E. Cho, Patrick J McLaren, A. Benzie, Wareef Kabbani, D. Jeyarajah
{"title":"An Unusual Case of Biliary Cystadenoma","authors":"Nicholson Brant, M. Darwish, H. Osman, E. Cho, Patrick J McLaren, A. Benzie, Wareef Kabbani, D. Jeyarajah","doi":"10.14740/jcs431","DOIUrl":"https://doi.org/10.14740/jcs431","url":null,"abstract":"","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"74 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88909347","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A Large Myofibroblastoma of the Breast in a Premenopausal Woman: A Case Report and Review of the Literature","authors":"Zein B. Sheikh, Roqaia M. Nafea, Ahmed S. Alsehli","doi":"10.14740/jcs465","DOIUrl":"https://doi.org/10.14740/jcs465","url":null,"abstract":"","PeriodicalId":93115,"journal":{"name":"Journal of current surgery","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"88025199","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：